drugset / Trial / NCT01308021
Clinical Efficacy and Safety of gpASIT+TM to Treat Seasonal Allergic Rhinoconjunctivitis
RandomizedParallel-groupDouble-blindPrevention
Summary
The purpose of the study is to evaluate the efficacy and safety of grass pollen-derived peptides administrated orally to treat seasonal allergic rhinoconjunctivitis.
Timeline
- Start
- 2010-12
- Primary completion
- 2011-10
- Completion
- 2011-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | gpASIT+TM | Peptide | 400 ug | Oral |
| Subject | gpASIT+TM | Peptide | 800 ug | Oral |